专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2007110782A1 MUSCARINIC RECEPTOR ANTAGONISTS 审中-公开
标题翻译：肌肉受体拮抗剂
公开(公告)号：WO2007110782A1
公开(公告)日：2007-10-04
申请号：PCT/IB2007/050003
申请日：2007-01-02
申请人： RANBAXY LABORATORIES LIMITED , KUMAR, Naresh , CLIFFE, Ian, Anthony , SALMAN, Mohammad , PALLE, Venkata, P. , KAUR, Kirandeep , SHEJUL, Yogesh, D. , CHUGH, Anita , GUPTA, Suman , RAY, Abhijit , MALHOTRA, Shivani , SHIRUMALLA, Raj, Kumar
发明人： KUMAR, Naresh , CLIFFE, Ian, Anthony , SALMAN, Mohammad , PALLE, Venkata, P. , KAUR, Kirandeep , SHEJUL, Yogesh, D. , CHUGH, Anita , GUPTA, Suman , RAY, Abhijit , MALHOTRA, Shivani , SHIRUMALLA, Raj, Kumar
IPC分类号： C07D487/08 , A61K31/403
CPC分类号： C07D209/52
摘要： This present invention generally relates to muscarinic receptor antagonists, which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to the process for the preparation of disclosed compounds, pharmaceutical compositions containing the disclosed compounds, and the methods for treating diseases mediated through muscarinic receptors.
摘要翻译：本发明一般涉及毒蕈碱受体拮抗剂，其可用于治疗通过毒蕈碱受体介导的呼吸，泌尿和胃肠系统的各种疾病，以及其它用途。本发明还涉及制备所公开的化合物的方法，含有所公开的化合物的药物组合物，以及用于治疗通过毒蕈碱受体介导的疾病的方法。

2. 发明申请

WO2012038980A3 FUSED TRICYCLIC COMPOUNDS AS ADENOSINE RECEPTOR ANTAGONIST 审中-公开
公开(公告)号：WO2012038980A3
公开(公告)日：2012-03-29
申请号：PCT/IN2011/000657
申请日：2011-09-22
申请人： ADVINUS THERAPEUTICS LIMITED , BARAWKAR, Dinesh , BASU, Sujay , RAMDAS, Vidya , NAYKODI, Minakshi , PATEL, Meena , SHEJUL, Yogesh , THORAT, Sachin , PANMAND, Anil
发明人： BARAWKAR, Dinesh , BASU, Sujay , RAMDAS, Vidya , NAYKODI, Minakshi , PATEL, Meena , SHEJUL, Yogesh , THORAT, Sachin , PANMAND, Anil
IPC分类号： C07D487/14 , A61K31/519 , A61K31/52 , A61K31/522 , A61P25/16 , A61P25/28
摘要： The present disclosure relates to fused tricyclic compounds of formula (I) or its tautomers, polymorphs, stereoisomers, prodrugs, solvate or a pharmaceutically acceptable salts, or pharmaceutical compositions containing them and methods of treating conditions and diseases that are mediated by thereof as A2A adenosine receptor antagonists. The compounds of the present disclosure are useful in the treatment, prevention or suppression of diseases and disorders that may be susceptible to improvement by the mediation of adenosine A2A receptor. Such conditions include, but are not limited to, Parkinsons disease, restless leg syndrome, Alzheimers disease, neurodegenerative disorder, inflammation, wound healing, dermal fibrosis, nocturnal myoclonus, cerebral ischaemia, myocardial ischemia, Huntington's disease, multiple system atrophy, corticobasal degeneration, Wilson's disease or other disorders of basal ganglia which results in dyskinesias, post traumatic stress disorder, hepatic cirrhosis, sepsis, spinal cord injury, retinopathy, hypertension, social memory impairment, depression, neuroprotection, narcolepsy or other sleep related disorders, attention deficit hyperactivity disorder, drug addiction, post traumatic stress disorder and vascular injury and the like. The present disclosure also relates to methods for the preparation of such compounds, and to pharmaceutical compositions containing them.

3. 发明申请

WO2008029349A3 MUSCARINIC RECEPTOR ANTAGONISTS 审中-公开
标题翻译：肌肉受体拮抗剂
公开(公告)号：WO2008029349A3
公开(公告)日：2008-07-17
申请号：PCT/IB2007053561
申请日：2007-09-04
申请人： RANBAXY LAB LTD , KUMAR NARESH , KAUR KIRANDEEP , SHEJUL YOGESH D , RAY ABHIJIT , GUPTA SUMAN , MALHOTRA SHIVANI , SHIRUMALLA RAJKUMAR
发明人： KUMAR NARESH , KAUR KIRANDEEP , SHEJUL YOGESH D , RAY ABHIJIT , GUPTA SUMAN , MALHOTRA SHIVANI , SHIRUMALLA RAJKUMAR
IPC分类号： C07D209/12 , A61K31/403 , A61K31/439 , A61P3/04 , A61P3/10 , A61P11/00 , A61P13/00 , C07D209/14 , C07D221/24
CPC分类号： C07D221/24 , C07D209/12 , C07D209/14
摘要： The present invention generally relates to muscarinic receptor antagonists, which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The present invention also relates to processes for preparing compounds described herein, pharmaceutical compositions thereof, and methods for treating diseases mediated throug muscarinic receptors. Formula (I) or a pharmaceutically accepted salt, pharmaceutically acceptable solvate, enantiomers, diastereomer, polymorph or N-oxide thereof, wherein X is.
摘要翻译：本发明一般涉及毒蕈碱受体拮抗剂，其可用于治疗通过毒蕈碱受体介导的呼吸，泌尿和胃肠系统的各种疾病，以及其它用途。本发明还涉及制备本文所述的化合物的方法，其药物组合物和用于治疗介导的毒蕈碱受体的疾病的方法。式（I）或其药学上可接受的盐，药学上可接受的溶剂合物，对映异构体，非对映体，多晶型物或N-氧化物，其中X为。

4. 发明申请

WO2012038980A2 FUSED TRICYCLIC COMPOUNDS AS ADENOSINE RECEPTOR ANTAGONIST 审中-公开
标题翻译：作为腺苷受体拮抗剂的融合三聚体化合物
公开(公告)号：WO2012038980A2
公开(公告)日：2012-03-29
申请号：PCT/IN2011000657
申请日：2011-09-22
申请人： ADVINUS THERAPEUTICS LTD , BARAWKAR DINESH , BASU SUJAY , RAMDAS VIDYA , NAYKODI MINAKSHI , PATEL MEENA , SHEJUL YOGESH , THORAT SACHIN , PANMAND ANIL
发明人： BARAWKAR DINESH , BASU SUJAY , RAMDAS VIDYA , NAYKODI MINAKSHI , PATEL MEENA , SHEJUL YOGESH , THORAT SACHIN , PANMAND ANIL
IPC分类号： C07D487/14
CPC分类号： C07D487/14 , A61K31/519 , A61K31/5377 , A61K45/06 , C07D519/00
摘要： The present disclosure relates to fused tricyclic compounds of formula (I) or its tautomers, polymorphs, stereoisomers, prodrugs, solvate or a pharmaceutically acceptable salts, or pharmaceutical compositions containing them and methods of treating conditions and diseases that are mediated by thereof as A2A adenosine receptor antagonists. [Formula should be inserted here] The compounds of the present disclosure are useful in the treatment, prevention or suppression of diseases and disorders that may be susceptible to improvement by the mediation of adenosine A2A receptor. Such conditions include, but are not limited to, Parkinsons disease, restless leg syndrome, Alzheimers disease, neurodegenerative disorder, inflammation, wound healing, dermal fibrosis, nocturnal myoclonus, cerebral ischaemia, myocardial ischemia, Huntington's disease, multiple system atrophy, corticobasal degeneration, Wilson's disease or other disorders of basal ganglia which results in dyskinesias, post traumatic stress disorder, hepatic cirrhosis, sepsis, spinal cord injury, retinopathy, hypertension, social memory impairment, depression, neuroprotection, narcolepsy or other sleep related disorders, attention deficit hyperactivity disorder, drug addiction, post traumatic stress disorder and vascular injury and the like. The present disclosure also relates to methods for the preparation of such compounds, and to pharmaceutical compositions containing them.
摘要翻译：本公开涉及式（I）的稠合三环化合物或其互变异构体，多晶型物，立体异构体，前药，溶剂化物或药学上可接受的盐或含有它们的药物组合物以及将由其介导的病症和疾病作为A2A腺苷的方法受体拮抗剂。 [公式应在此插入]本公开的化合物可用于治疗，预防或抑制可能通过腺苷A2A受体介导而改善的疾病和病症。这些病症包括但不限于：帕金森病，不宁腿综合征，阿尔茨海默病，神经变性疾病，炎症，伤口愈合，真皮纤维化，夜间肌阵挛，脑缺血，心肌缺血，亨廷顿舞蹈病，多系统萎缩，皮质基底变性，威尔逊病或基底节神经节的其他疾病，导致运动障碍，创伤后应激障碍，肝硬化，败血症，脊髓损伤，视网膜病变，高血压，社会记忆障碍，抑郁，神经保护，发作性睡眠或其他睡眠相关疾病，注意缺陷多动障碍，药物成瘾，创伤后应激障碍和血管损伤等。本公开还涉及制备这些化合物的方法以及含有它们的药物组合物。

5. 发明申请

WO2008104955A1 AZONIATRICYCLO [3.3.1.0] NONANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS 审中-公开
标题翻译：亚麻酸盐[3.3.1.0]作为肌酸受体拮抗剂的非衍生物
公开(公告)号：WO2008104955A1
公开(公告)日：2008-09-04
申请号：PCT/IB2008/050734
申请日：2008-02-28
申请人： RANBAXY LABORATORIES LIMITED , KUMAR, Naresh , KAUR, Kirandeep , KAUR, Jaskiran , AERON, Shelly , SHEJUL, Yogesh, D. , RAY, Abhijit , GUPTA, Suman , MALHOTRA, Shivani , SHIRUMALLA, Rajkumar
发明人： KUMAR, Naresh , KAUR, Kirandeep , KAUR, Jaskiran , AERON, Shelly , SHEJUL, Yogesh, D. , RAY, Abhijit , GUPTA, Suman , MALHOTRA, Shivani , SHIRUMALLA, Rajkumar
IPC分类号： C07D451/10 , A61K31/46 , A61P11/06
CPC分类号： C07D451/10
摘要： This present invention relates to muscarinic receptor antagonists of formula (I), which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to the process for the preparation of the disclosed compounds, pharmaceutical composition containing the disclosed compounds and methods for treating diseases mediated through muscarinic receptors.
摘要翻译：本发明涉及式（I）的毒蕈碱受体拮抗剂，其可用于治疗通过毒蕈碱受体介导的呼吸，泌尿和胃肠系统的各种疾病，以及其它用途。本发明还涉及制备所公开的化合物的方法，包含所公开的化合物的药物组合物和用于治疗通过毒蕈碱受体介导的疾病的方法。

6. 发明申请

WO2011055391A1 SUBSTITUTED FUSED PYRIMIDINE COMPOUNDS, ITS PREPARATION AND USES THEREOF 审中-公开
标题翻译：取代的熔融吡啶化合物，其制备及其用途
公开(公告)号：WO2011055391A1
公开(公告)日：2011-05-12
申请号：PCT/IN2010/000732
申请日：2010-11-09
申请人： ADVINUS THERAPEUTICS PRIVATE LIMITED , RAMDAS, Vidya , KOUL, Summon , BASU, Sujay , WAMAN, Yogesh , SHEJUL, Yogesh , BARAWKAR, Dinesh , PALLE, Venkata Poornapragnacharyulu
发明人： RAMDAS, Vidya , KOUL, Summon , BASU, Sujay , WAMAN, Yogesh , SHEJUL, Yogesh , BARAWKAR, Dinesh , PALLE, Venkata Poornapragnacharyulu
IPC分类号： C07D473/06 , C07D473/18 , A61K31/522 , A61P11/00
CPC分类号： C07D473/18 , C07D473/06
摘要： The present invention provides substituted fused pyrimidine compounds of formula (I), their tautomers, polymorphs, stereoisomers, prodrugs, solvates, pharmaceutically acceptable salts, pharmaceutical compositions containing them and methods of treating conditions and diseases that are mediated by adenosine receptor (AR) activity. The present invention also provides process of preparation of formula (I).
摘要翻译：本发明提供式（I）的取代的稠合嘧啶化合物，其互变异构体，多晶型物，立体异构体，前药，溶剂化物，药学上可接受的盐，含有它们的药物组合物和治疗由腺苷受体（AR）活性介导的病症和疾病的方法。本发明还提供式（I）的制备方法。

7. 发明申请

WO2008029349A2 MUSCARINIC RECEPTOR ANTAGONISTS 审中-公开
标题翻译：肌肉受体拮抗剂
公开(公告)号：WO2008029349A2
公开(公告)日：2008-03-13
申请号：PCT/IB2007/053561
申请日：2007-09-04
申请人： RANBAXY LABORATORIES LIMITED , KUMAR, Naresh , KAUR, Kirandeep , SHEJUL, Yogesh, D. , RAY, Abhijit , GUPTA, Suman , MALHOTRA, Shivani , SHIRUMALLA, Rajkumar
发明人： KUMAR, Naresh , KAUR, Kirandeep , SHEJUL, Yogesh, D. , RAY, Abhijit , GUPTA, Suman , MALHOTRA, Shivani , SHIRUMALLA, Rajkumar
CPC分类号： C07D221/24 , C07D209/12 , C07D209/14
摘要： The present invention generally relates to muscarinic receptor antagonists, which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The present invention also relates to processes for preparing compounds described herein, pharmaceutical compositions thereof, and methods for treating diseases mediated through muscarinic receptors.
摘要翻译：本发明一般涉及毒蕈碱受体拮抗剂，其可用于治疗通过毒蕈碱受体介导的呼吸，泌尿和胃肠系统的各种疾病，以及其它用途。本发明还涉及制备本文所述化合物的方法，其药物组合物，以及用于治疗通过毒蕈碱受体介导的疾病的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式